| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T692 |
0-15 |
Sentence |
denotes |
Acknowledgments |
| T693 |
16-98 |
Sentence |
denotes |
We apologize to all authors whose work we could not cite due to space limitations. |
| T694 |
99-202 |
Sentence |
denotes |
Trainee (PhD and MD/PhD or postdocs) and faculty contributing authors are listed in alphabetical order. |
| T695 |
203-231 |
Sentence |
denotes |
Illustrations are by Jill K. |
| T696 |
232-294 |
Sentence |
denotes |
Gregory and used with permission of Mount Sinai Health System. |
| T697 |
295-550 |
Sentence |
denotes |
We would like to acknowledge funding sources including Fastgrant (M.M.), NCI Cancer Center Support Grant Supplement (M.M., R.M.S.) Burroughs Wellcome Fund (R.M.S.), NIH Director’s Early Independence Award (R.M.S.) and NIH R01AI081848 (N.V., N.B., B.D.G.). |
| T698 |
552-576 |
Sentence |
denotes |
Declaration of Interests |
| T699 |
577-803 |
Sentence |
denotes |
N.B. serves as an advisor/board member for Neon, Checkpoint Sciences, Primevax, Novartis, Array BioPharma, Roche, Avidea, Boeringer Ingelheim, Rome Therapeutics, Roswell Park, and the Parker Institute for Cancer Immunotherapy. |
| T700 |
804-914 |
Sentence |
denotes |
N.B. receives research support from the Parker Insitute, Novocure, Celldex, Genentech, Oncovir, and Regeneron. |
| T701 |
915-1034 |
Sentence |
denotes |
M.M. serves as an advisor/board member for Celsius, Pionyr, Compugen, Myeloids and Innate pharma and ad hoc for Takeda. |
| T702 |
1035-1104 |
Sentence |
denotes |
M.M. receives research support from Regeneron, Takeda, and Genentech. |
| T703 |
1105-1170 |
Sentence |
denotes |
A.M. has equity in Gilead Sciences and Regeneron Pharmaceuticals. |
